Table 2. Cases with discordant results for detection of BCR-ABL1 fusion transcripts using the BML and in-house methods.
| Patient # | Timing of detection (month) | IS % ratio | TKI type after recurrence | ||
|---|---|---|---|---|---|
| BML method | In-house method | In-house method | ODK-1201 | ||
| 21 | 15 | 12 | 0.0201 | ND | Dasatinib |
| 22 | 18 | 5 | 0.0041 | ND | Dasatinib |
| 23 | 1 | 0 | 0.0081 | NA | Dasatinib |
| 24 | 11 | 4 | 0.0184 | 0.0124 | Dasatinib |
| 25 | 5 | 3 | 0.0584 | 0.0107 | Dasatinib |
| 26 | 1 | 0 | 0.0326 | 0.0021 | Dasatinib |
| 27 | 4 | 2 | 0.0269 | 0.0061 | Dasatinib |
| 28 | 15 | 12 | 0.0141 | 0.0054 | Dasatinib |
| 29 | 2 | 1 | 0.0115 | 0.0040 | Dasatinib |
| 30 | 1 | 0 | 0.0127 | NA | Imatinib |
| 31 | 3 | 2 | 0.0284 | 0.0186 | Dasatinib |
| 32 | 1 | 0 | 0.0120 | ND | Imatinib |
| 33 | 5 | 4 | 0.0353 | 0.0214 | Dasatinib |
| 34 | 4 | 3 | 0.0481 | 0.0039 | Dasatinib |
| 35 | 2 | 0 | 0.0069 | 0.0024 | Imatinib |
| 36 | 1 | 0 | 0.0194 | 0.0054 | Dasatinib |
| 37 | 6 | 3 | 0.0010 | 0.0049 | Dasatinib |
| 38 | 3 | 0 | 0.0082 | ND | Dasatinib |
| 39 | 1 | 0 | 0.0175 | 0.0058 | Imatinib |
| 40 | 1 | 0 | 0.0084 | 0.0045 | Dasatinib |
| 41 | 3 | 1 | 0.0019 | ND | Dasatinib |
IS, International scale; ND, not detected; NA, not applicable.
Timing of detection: time point when BCR-ABL1 fusion transcripts were detected.